Transcutaneous Electrical Nerve Stimulation During Outpatient Endometrial Biopsy

Sponsor
Duke University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05472740
Collaborator
(none)
160
2
16

Study Details

Study Description

Brief Summary

The purpose of this study is to see whether transcutaneous electrical nerve stimulation (or TENS) reduces pain during an endometrial biopsy. A TENS unit is an over-the-counter, FDA approved device that sends low-level electrical impulses through the skin to reduce the amount of discomfort experienced during procedures. A TENS unit is very low-risk and used in a lot of ways, including for chronic pain, after surgery, and during labor. Since there is no standard way of managing discomfort during an endometrial biopsy, the investigators think that TENS might be helpful.

Participating in the study may require some additional time in clinic to answer research-related questions. Subjects will be asked to answer demographic questions (which will be combined anonymously) before and after the procedure, as well as rate subject's pain at different time points during the procedure.

The biggest benefit in participating is that subject's discomfort might be lower during and after the procedure. Subjects may not benefit from participating in this study. There is a small risk of a skin reaction from wearing the TENS pads.

Condition or Disease Intervention/Treatment Phase
  • Device: TENS 7000
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Masking Description:
The participant and the provider completing the endometrial biopsy will be blinded to what group (intervention or placebo) that the subject is in. The clinical research coordinator assisting with the study and placement of the TENS will not be blinded.
Primary Purpose:
Treatment
Official Title:
Transcutaneous Electrical Nerve Stimulation for Analgesia During Outpatient Endometrial Biopsy: a Randomized Controlled Trial
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active TENS

Participants will be connected to a TENS 7000 that is turned on and working

Device: TENS 7000
TENS device to be used in both the active and placebo groups

Placebo Comparator: Placebo TENS

Participants will be connected to a TENS 7000 however it will not be connected / will not be working

Device: TENS 7000
TENS device to be used in both the active and placebo groups

Outcome Measures

Primary Outcome Measures

  1. Pain after Endometrial Biopsy, as measured by Visual Analogue Scale (VAS) [Immediately after endometrial biopsy]

    Scores are measured on a 100 mm VAS. The VAS ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain

Secondary Outcome Measures

  1. Number of participants who find the intervention acceptable based on survey response [End of procedure]

    A 0 to 100 mm scale similar to VAS to assess acceptability of TENS intervention

  2. Number of participants who find the intervention tolerable based on survey response [End of procedure]

    A 0 to 100 mm scale similar to VAS to assess tolerability of TENS intervention

  3. Change in Pain, as measured by Visual Analogue Scale (VAS) across different time intervals [Speculum placement, tenaculum placement, 5 minutes after biopsy, and 15 minutes after biopsy]

    Scores are measured on a 100 mm VAS. The VAS ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain

  4. Provider satisfaction with the procedure [End of procedure]

    A 0 to 100 mm scale similar to VAS to assess provider satisfaction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • at least 18 years old

  • undergoing an outpatient endometrial biopsy

  • Duke gynecological oncology clinics and general gynecology clinic

Exclusion Criteria:
  • age younger than 18 years

  • unable to follow study instructions and/or independently adjust TENS settings

  • cutaneous damage at the TENS application site

  • pacemaker or automatic implanted cardiac defibrillator

  • inability to understand or declines to sign the informed consent form

  • previous personal experience using a TENS unit

  • pregnant women (will be excluded as part of standard of care for endometrial evaluation)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Laura Havrilesky, MD, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT05472740
Other Study ID Numbers:
  • Pro00111100
First Posted:
Jul 25, 2022
Last Update Posted:
Jul 25, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Duke University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 25, 2022